Paying the Right Price in Biotech Acquisitions
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 76 (Table of Contents)
Published: 1 Oct-2006
DOI: 10.3833/pdr.v2006.i76.445 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
In this feature, Rupert Winckler, from Healthcare Investment Banking at Piper Jaffray, discusses the reasons why the forecast M&A (merger and acquisition) boom in the biotech industry never happened, the recent run of acquisitions by big pharma of development-stage biotechs, and how much these big pharmas are paying for the biotechs...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS